



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

Robert M. LORENCE et al

Serial No. 08/260,536

Filed: June 16, 1994

Atty. Ref.: 2370-11

TC/A.U.: 1648

Examiner: Le, Emily M.

For: METHODS FOR TREATING AND DETECTING CANCER USING  
VIRUSES

\* \* \* \* \*

October 18, 2004

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449.


This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lfm

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

10/19/2004 SSESHE1 00000154 08260536 180.00 DP  
01 FC:1806

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-11

08/260,536

APPLICANT


Robert M. LORENCE et al

FILING DATE

TC/A.U.

June 16, 1994

1648



(Use General sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Povlsen, C.O.; "Status of Chemotherapy, Radiotherapy, Endocrine Therapy, and Immunotherapy Studies of Human Cancer in the Nude Mouse"; <i>The Nude Mouse in Experimental and Clinical Research</i> ; Academic Press, New York, San Francisco, London; pp. 437-457 (1978).
	Thorne, S.H., et al; "Future Directions for the Field of Oncolytic Virotherapy: A Perspective on the Use of Vaccinia Virus"; <i>Expert Opin. Biol. Ther.</i> ; Vol. 4, No. 8; pp 1307-1321 (2004).
	Poster (ASCO Meeting); "Slow Intravenous Infusion of PV701, An Oncolytic Virus: Final Results of a Phase Study"; <i>2004 Am. Soc. Clin. Oncology (ASCO) Mtg.</i>
	Schirmacher, V., et al; "Virus Potentiation of Tumor Vaccine T-Cell Stimulatory Capacity Requires Cell Surface Binding but not Infection"; <i>Clinical Cancer Research</i> ; Vol. 3; pp. 1135-1148 (1997).
	Zorn, U., et al; "Induction of Cytokines and Cytotoxicity Against Tumor Cells by Newcastle Disease Virus"; <i>Cancer Biotherapy</i> ; Vol. 9, No. 3; pp. 225-235 (1994).
	Zorn, U., et al; "Active Specific Immunotherapy of Renal Cell Carcinoma: Cellular and Humoral Immune Responses"; <i>Cancer Biotherapy &amp; Radiopharmaceuticals</i> ; Vol. 12, No. 3; pp. 157-165 (1997).
	Plager, C., et al; "Adjuvant Immunotherapy with Newcastle Disease Virus Oncolysate of M.D. Anderson (MDAH) Stage III-B Malignant Melanoma"; Head and Neck, Sarcoma, Melanoma, and Other Solid Tumors; <i>Proceedings of ASCO</i> ; Vol. 4; C-584 p. 150 (1985).
	Plager, C., et al; "Adjuvant Immunotherapy with Newcastle Disease Virus Oncolysate of M.D. Anderson (MDAH) Stage III-B Malignant Melanoma"; Head and Neck, Sarcoma, Melanoma, and Other Solid Tumors; <i>Proceedings of ASCO</i> ; Vol. 5; 534 p. 137 (1986).
	Krishnamurthy, S., et al; "Newcastle Disease Virus as an Oncolytic Agent: Mechanism of Viral Infection, Growth and Oncolysis"; <i>American Society for Virology 21<sup>st</sup> Annual Meeting, University of Kentucky, Lexington, KY, July 20-24, 2002, Scientific Program and Abstracts</i> ; p. 90.
	Batliwalla, F.M., et al; "A 15-Year Follow-up of AJCC Stage III Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus (NDV) Oncolysate and Determination of Alternations in the CD8 T Cell Repertoire"; <i>Molecular Medicine</i> ; Vol. 4; pp. 783-794 (1998).
	Bonaccorsi, P., et al; "Management of High-risk Melanoma"; <i>Medical Dermatology</i> ; Vol. 19, No. 4; pp 727-735 (2001).

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.